Prognostic value of miR-96 in patients with acute myeloid leukemia.
Prognostic value of miR-96 in patients with acute myeloid leukemia.
复制标题
DOI：
10.1186/1746-1596-9-76
复制
发表时间：
2014-03-29
影响因子：
2.6
通讯作者：
Chen YX
中科院分区：
文献类型：
--
作者：
Zhao J;Lu Q;Zhu J;Fu J;Chen YX
MiRNA(MiR)-96的异常表达与多种实体肿瘤的发生和发展有关。然而，miR-96在急性髓系白血病(AML)中的表达及其预后价值却鲜为人知。因此，本研究旨在探讨miR-96表达与AML临床病理特征及预后的关系。采用实时荧光定量RT-PCR方法检测86例初诊AML患者骨髓或外周血单个核细胞miR-96的表达水平。与正常对照组相比，初诊急性髓系白血病患者miR-96的表达显著下调(P <； 0.001)。在14个诊断/CR配对样本的分析中，发现治疗后患者miR-96的表达水平明显高于治疗前(P <； 0.001)。此外，较低的miR-96水平与较高的白细胞计数、骨髓母细胞计数(P <； 分别为0.001和0.022)以及较低的血红蛋白和血小板计数(分别为P = 0.036和0.033)相关。虽然低表达组的CR率较低(53.85%vs70.0%)，但两组间差异无统计学意义(P = 0.213)。在中位随访20个月期间，低表达组的无复发生存期(RF)(P = 0.038)和总生存期(OS)(P = 0.022)均低于高表达组。我们的数据表明miR-96在新诊断的AML患者中表达下调，并与白血病负担、RFS和OS相关。提示miR-96检测有可能成为AML预后和监测的潜在生物标志物。本文的虚拟幻灯片(S)可在此处找到：http://www.diagnosticpathology.diagnomx.eu/vs/1434808553949498
Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression with clinicopathological features and prognosis of AML. Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML. Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups (P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS) (P = 0.022) compared with the high-expression group during a median follow-up of 20 months. Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1434808553949498
登录
查看更多内容
影响因子：
64.8
作者：
Lu, J;Getz, G;Golub, TR
通讯作者：
Golub, TR
影响因子：
3.4
作者：
Wang, Yi;Luo, Hongmei;Yang, Luoyan
通讯作者：
Yang, Luoyan
影响因子：
20.3
作者：
Garzon, Ramiro;Volinia, Stefano;Croce, Carlo M.
通讯作者：
Croce, Carlo M.
影响因子：
45.3
作者：
Marcucci, Guido;Maharry, Kati;Bloomfield, Clara D.
通讯作者：
Bloomfield, Clara D.
影响因子：
3.7
作者：
Dixon-McIver A;East P;Mein CA;Cazier JB;Molloy G;Chaplin T;Andrew Lister T;Young BD;Debernardi S
通讯作者：
Debernardi S